Speciality Medicines IPO Subscription Reaches 1.01x with Mixed Category Response
Speciality Medicines IPO achieved 1.01x overall subscription with mixed category performance. QIB category subscribed exactly 1x while bHNI showed strong interest at 2.68x. Retail and sHNI categories remained undersubscribed at 0.19x and 0.1x respectively, with no employee participation.
*this image is generated using AI for illustrative purposes only.
Speciality Medicines' initial public offering has recorded an overall subscription of 1.01x, reflecting a measured response from the investment community across various investor categories.
Subscription Performance by Category
The IPO subscription data shows distinct patterns across different investor segments:
| Category | Subscription Level |
|---|---|
| Qualified Institutional Buyers (QIB) | 1x |
| Non-Institutional Buyers (bHNI) | 2.68x |
| Non-Institutional Buyers (sHNI) | 0.1x |
| Retail | 0.19x |
| Employees | 0x |
| Total Subscribed | 1.01x |
Category-wise Analysis
The Qualified Institutional Buyers category achieved full subscription at exactly 1x, indicating measured institutional interest. Among Non-Institutional Buyers, the big HNI segment demonstrated notable enthusiasm with 2.68x subscription, significantly oversubscribing their allocated portion.
Conversely, the small HNI category recorded minimal participation at 0.1x subscription, while the retail investor segment showed limited interest with 0.19x subscription. The employee category registered no subscription activity during the period.
Overall Market Response
The overall subscription level of 1.01x positions the Speciality Medicines IPO as marginally oversubscribed, with the strong performance in the big HNI category helping to offset the undersubscription in retail and small HNI segments. The balanced institutional participation at 1x subscription provides stability to the overall subscription numbers.
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
